Is ashwagandha safe and effective for treating anxiety in children or adolescents?

Ashwagandha for Pediatric Anxiety

Ashwagandha should not be used for treating anxiety in children or adolescents, as there is no evidence supporting its safety or efficacy in this population, and established first-line treatments with proven benefit exist.

Evidence-Based Treatment Recommendations

The American Academy of Child and Adolescent Psychiatry (AACAP) 2020 clinical practice guidelines clearly establish the evidence-based treatments for pediatric anxiety 1:

First-Line Treatment Algorithm

For mild to moderate anxiety:

• Cognitive-behavioral therapy (CBT) is the first-line treatment with considerable empirical support for safety and effectiveness 1

For severe anxiety or when quality CBT is unavailable:

• Selective serotonin reuptake inhibitors (SSRIs) are the alternative treatment consideration with substantial evidence 1
• Serotonin-norepinephrine reuptake inhibitors (SNRIs) have some empirical support as an additional option 1

For optimal outcomes:

• Combination treatment (CBT + SSRI) may be more effective than either treatment alone 1

Why Ashwagandha Is Not Recommended

Complete Absence of Pediatric Evidence

The available research on ashwagandha for anxiety has critical limitations for pediatric use:

• All clinical trials were conducted exclusively in adults aged 18-65 years 2, 3, 4, 5
• The single animal study in adolescent rats 6 cannot be extrapolated to human children
• No safety data exist for children or adolescents regarding appropriate dosing, adverse effects, or long-term consequences
• The AACAP guidelines make no mention of ashwagandha or other herbal adaptogens as treatment options [1-1]

Safety Concerns Specific to Pediatric Use

Recent comprehensive safety reviews identify concerning risks 7:

Hepatotoxicity: Liver toxicity has been reported, particularly with prolonged use—a critical concern in developing children

Endocrine disruption: Ashwagandha affects thyroid function and can cause thyrotoxicosis and adrenal suppression 7—particularly problematic during critical developmental periods

Drug interactions: Metabolized via cytochrome P450 enzymes, creating potential interactions with medications children may be taking for comorbid conditions 8, 7

Gastrointestinal effects: Common adverse events include epigastric pain, loose stools, nausea, and decreased appetite 8—which can impact growth and nutrition in children

Lack of standardization: Dosing regimens are not established for pediatric populations, and formulations vary widely in withanolide content 7

Clinical Pitfalls to Avoid

Do not delay evidence-based treatment: Untreated pediatric anxiety disorders lead to significant impairments in social, educational, occupational, and mental health outcomes extending into adulthood 1

Do not assume adult data applies to children: The developing brain, different metabolic profiles, and ongoing physical growth make children fundamentally different from adults in drug response and safety profiles

Do not use complementary therapies as substitutes: While mind-body therapies like guided imagery and mindfulness have some supportive evidence as adjuncts for pediatric anxiety 9, they should not replace proven first-line treatments

Recommended Clinical Approach

When parents inquire about ashwagandha for their child's anxiety:

1. Acknowledge their interest in exploring treatment options while explaining the absence of pediatric evidence

2. Redirect to evidence-based treatments: Initiate CBT for mild-moderate anxiety; consider SSRIs for severe presentations or when CBT is unavailable 1

3. Consider adjunctive mind-body practices with some pediatric evidence: mindfulness meditation, guided imagery, or yoga may provide additional benefits for stress management and self-regulation 9

4. Monitor closely: Anxiety disorders in children often have comorbidities (depression, ADHD, learning disorders) requiring comprehensive assessment and potentially multifaceted treatment plans 1

The evidence unequivocally supports CBT and SSRIs as safe and effective treatments for pediatric anxiety, while ashwagandha lacks any pediatric safety or efficacy data and carries potential risks that are particularly concerning in developing children.